Dr. Michael Kalos is a recognized international key opinion leader in the fields of immunotherapy and biomarkers.
Previously, Dr. Kalos was Executive Vice President and Head of Research and Development at ArsenalBio. He also served as Vice President, Immunooncology and Oncology Cell Therapies, at Janssen, the Pharmaceutical Companies of Johnson and Johnson, and chief scientific officer at Eli Lilly & Company. He fleshed out their immuno-oncology strategy, integrated their programs, and made them more comprehensive. He has also led efforts to improve the way that doctors evaluate early stage immunotherapy protocols, and has also been involved in developing promising immunotherapies such as CAR T cells.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Kalos serves on the Cancer Immunotherapy Consortium (CIC) Steering Committee.
The [strategies] we’ve developed don’t target the T cell, they target the microenvironment, which we now know is a critical component for the success of immunotherapy.
¡Hagamos correr la voz sobre la inmunoterapia! Haga clic para compartir esta página con su comunidad.